EXTON, PA -- (MARKET WIRE) -- January 31, 2007 -- Rheologics Technologies, Inc. (PINKSHEETS: RTGI) (“Rheologics,” the “Company”), the leader in the study of blood viscosity and its relationship to vascular diseases, announced today the results of a study performed at the University of Chicago using the Rheolog®, the Company’s proprietary blood viscometer. The research demonstrated significantly higher blood viscosity in scleroderma patients over health controls and, among scleroderma patients, higher blood viscosity in patients having active digital (finger) ulcers over those scleroderma patients that did not.
